Table 1 Comparison of clinicopathological features of 156 CLL/SLL patients with or without MYD88 mutations.
Features | WT (n = 100) | A (L265P, n = 38) | B (Non-L265P, n = 18) | P-value | |||
|---|---|---|---|---|---|---|---|
WT vs. A | WT vs. B | A vs. B | |||||
Age @ dx Median Range | 58.5 | 55 | 61 | 0.0077 | NS | 0.0071 | |
(30–81) | (23–73) | (51–79) | |||||
M:F | 2.2:1 (69:31) | 4.4:1 (31:7) | 2:1 (12:6) | NS | NS | NS | |
Rai stage III–IV @ dx | 14% (13/91) | 5% (2/38) | 6% (1/16) | NS | NS | NS | |
1° or 2° relative with CLL | 12% (10/83) | 11% (4/35) | 13% (2/15) | NS | NS | NS | |
ALC, × 109/L Median Range | 16.6 | 13.4 | 22.3 | NS | NS | NS | |
(1.3–328.6) | (2.0–238.8) | (0.3–90.8) | |||||
Serum Paraprotein + | 9% (9/100) | 11% (4/38) | 6% (1/18) | NS | NS | NS | |
Elevated β2-microglobulin | 62% (53/85) | 38% (14/37) | 56% (10/18) | 0.0173 | NS | NS | |
CD38+ | 47% (47/100) | 16% (6/38) | 17% (3/18) | 0.0008a | 0.0195 | NS | |
ZAP-70+ | 68% (65/95) | 23% (8/35) | 53% (9/17) | <0.0001a | NS | 0.0565 | |
Mutated IGHV | 39% (34/87) | 97% (35/36) | 63% (10/16) | <0.0001a | NS | 0.0022 | |
